CN109467538A - 环烯烃取代的杂芳环类化合物及其用途 - Google Patents

环烯烃取代的杂芳环类化合物及其用途 Download PDF

Info

Publication number
CN109467538A
CN109467538A CN201710801364.3A CN201710801364A CN109467538A CN 109467538 A CN109467538 A CN 109467538A CN 201710801364 A CN201710801364 A CN 201710801364A CN 109467538 A CN109467538 A CN 109467538A
Authority
CN
China
Prior art keywords
compound
formula
alkyl
halogen
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710801364.3A
Other languages
English (en)
Chinese (zh)
Inventor
苏慰国
戴广袖
肖坤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Ltd
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Priority to CN201710801364.3A priority Critical patent/CN109467538A/zh
Priority to CN202311036845.1A priority patent/CN117257809A/zh
Priority to TW107131525A priority patent/TWI816693B/zh
Priority to CN202311040510.7A priority patent/CN117024363A/zh
Priority to CA3073782A priority patent/CA3073782A1/en
Priority to AU2018329047A priority patent/AU2018329047B2/en
Priority to UAA202002089A priority patent/UA129118C2/uk
Priority to PE2020000280A priority patent/PE20200727A1/es
Priority to ARP180102548A priority patent/AR112794A1/es
Priority to US16/645,329 priority patent/US11414390B2/en
Priority to SG11202001642WA priority patent/SG11202001642WA/en
Priority to MX2020002505A priority patent/MX2020002505A/es
Priority to EP18853366.5A priority patent/EP3679020A4/en
Priority to BR112020004563-2A priority patent/BR112020004563A2/pt
Priority to CN201880057118.4A priority patent/CN111132967B/zh
Priority to PCT/CN2018/104531 priority patent/WO2019047909A1/en
Priority to CN202311036787.2A priority patent/CN116999441A/zh
Priority to JP2020513872A priority patent/JP7273030B6/ja
Priority to EA202090653A priority patent/EA202090653A1/ru
Priority to NZ762447A priority patent/NZ762447B2/en
Priority to CN202311036829.2A priority patent/CN117797156A/zh
Priority to KR1020207009621A priority patent/KR102566237B1/ko
Publication of CN109467538A publication Critical patent/CN109467538A/zh
Priority to IL272923A priority patent/IL272923B2/en
Priority to PH12020500408A priority patent/PH12020500408A1/en
Priority to CL2020000553A priority patent/CL2020000553A1/es
Priority to ZA2020/01448A priority patent/ZA202001448B/en
Priority to US17/747,925 priority patent/US12234211B2/en
Priority to JP2023072737A priority patent/JP7603740B2/ja
Priority to US19/050,772 priority patent/US20250223267A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201710801364.3A 2017-09-07 2017-09-07 环烯烃取代的杂芳环类化合物及其用途 Pending CN109467538A (zh)

Priority Applications (29)

Application Number Priority Date Filing Date Title
CN201710801364.3A CN109467538A (zh) 2017-09-07 2017-09-07 环烯烃取代的杂芳环类化合物及其用途
CN202311036787.2A CN116999441A (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
PCT/CN2018/104531 WO2019047909A1 (en) 2017-09-07 2018-09-07 HETEROAROMATIC COMPOUNDS SUBSTITUTED WITH CYCLOOLEFINS AND THEIR USE
CN202311040510.7A CN117024363A (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
CA3073782A CA3073782A1 (en) 2017-09-07 2018-09-07 Cycloolefin substituted heteroaromatic compounds and their use
AU2018329047A AU2018329047B2 (en) 2017-09-07 2018-09-07 Cycloolefin substituted heteroaromatic compounds and their use
UAA202002089A UA129118C2 (uk) 2017-09-07 2018-09-07 Циклоолефінозаміщені гетероароматичні сполуки та їх використання
PE2020000280A PE20200727A1 (es) 2017-09-07 2018-09-07 Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso
ARP180102548A AR112794A1 (es) 2017-09-07 2018-09-07 Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh
US16/645,329 US11414390B2 (en) 2017-09-07 2018-09-07 Cycloolefin substituted heteroaromatic compounds and their use
SG11202001642WA SG11202001642WA (en) 2017-09-07 2018-09-07 Cycloolefin substituted heteroaromatic compounds and their use
MX2020002505A MX2020002505A (es) 2017-09-07 2018-09-07 Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso.
EP18853366.5A EP3679020A4 (en) 2017-09-07 2018-09-07 CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USES
BR112020004563-2A BR112020004563A2 (pt) 2017-09-07 2018-09-07 compostos heteroaromáticos substituídos por ciclo-olefina e seu uso
CN201880057118.4A CN111132967B (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
CN202311036845.1A CN117257809A (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
KR1020207009621A KR102566237B1 (ko) 2017-09-07 2018-09-07 사이클로올레핀 치환된 헤테로방향족 화합물 및 그의 용도
JP2020513872A JP7273030B6 (ja) 2017-09-07 2018-09-07 シクロオレフィン置換複素芳香族化合物およびそれらの使用
EA202090653A EA202090653A1 (ru) 2017-09-07 2018-09-07 Циклоолефиновые замещённые гетероароматические соединения и их применение
NZ762447A NZ762447B2 (en) 2018-09-07 Cycloolefin substituted heteroaromatic compounds and their use
CN202311036829.2A CN117797156A (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
TW107131525A TWI816693B (zh) 2017-09-07 2018-09-07 環烯烴取代的雜芳環類化合物及其用途
IL272923A IL272923B2 (en) 2017-09-07 2020-02-26 Disubstituted cycloolefin heteroaromatic compounds and their uses
PH12020500408A PH12020500408A1 (en) 2017-09-07 2020-02-28 Cycloolefin substituted heteroaromatic compounds and their use
CL2020000553A CL2020000553A1 (es) 2017-09-07 2020-03-05 Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso.
ZA2020/01448A ZA202001448B (en) 2017-09-07 2020-03-06 Cycloolefin substituted heteroaromatic compounds and their use
US17/747,925 US12234211B2 (en) 2017-09-07 2022-05-18 Cycloolefin substituted heteroaromatic compounds and their use
JP2023072737A JP7603740B2 (ja) 2017-09-07 2023-04-26 シクロオレフィン置換複素芳香族化合物およびそれらの使用
US19/050,772 US20250223267A1 (en) 2017-09-07 2025-02-11 Cycloolefin substituted heteroaromatic compounds and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710801364.3A CN109467538A (zh) 2017-09-07 2017-09-07 环烯烃取代的杂芳环类化合物及其用途

Publications (1)

Publication Number Publication Date
CN109467538A true CN109467538A (zh) 2019-03-15

Family

ID=65634832

Family Applications (6)

Application Number Title Priority Date Filing Date
CN201710801364.3A Pending CN109467538A (zh) 2017-09-07 2017-09-07 环烯烃取代的杂芳环类化合物及其用途
CN201880057118.4A Active CN111132967B (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
CN202311036787.2A Pending CN116999441A (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
CN202311036845.1A Pending CN117257809A (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
CN202311036829.2A Pending CN117797156A (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
CN202311040510.7A Pending CN117024363A (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN201880057118.4A Active CN111132967B (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
CN202311036787.2A Pending CN116999441A (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
CN202311036845.1A Pending CN117257809A (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
CN202311036829.2A Pending CN117797156A (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途
CN202311040510.7A Pending CN117024363A (zh) 2017-09-07 2018-09-07 环烯烃取代的杂芳环类化合物及其用途

Country Status (20)

Country Link
US (3) US11414390B2 (enExample)
EP (1) EP3679020A4 (enExample)
JP (2) JP7273030B6 (enExample)
KR (1) KR102566237B1 (enExample)
CN (6) CN109467538A (enExample)
AR (1) AR112794A1 (enExample)
AU (1) AU2018329047B2 (enExample)
BR (1) BR112020004563A2 (enExample)
CA (1) CA3073782A1 (enExample)
CL (1) CL2020000553A1 (enExample)
EA (1) EA202090653A1 (enExample)
IL (1) IL272923B2 (enExample)
MX (1) MX2020002505A (enExample)
PE (1) PE20200727A1 (enExample)
PH (1) PH12020500408A1 (enExample)
SG (1) SG11202001642WA (enExample)
TW (1) TWI816693B (enExample)
UA (1) UA129118C2 (enExample)
WO (1) WO2019047909A1 (enExample)
ZA (1) ZA202001448B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111132967A (zh) * 2017-09-07 2020-05-08 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
WO2022095756A1 (zh) * 2020-11-09 2022-05-12 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
WO2023134686A1 (zh) * 2022-01-11 2023-07-20 正大天晴药业集团股份有限公司 一种1,3,5-三嗪衍生物的制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3074641A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555154A (en) * 1967-08-16 1971-01-12 Armour Pharma Preparations containing 6 - cycloalkylguanamines and methods for treating inflammatory conditions therewith
EP0361489A3 (en) 1988-09-30 1991-06-12 Chugai Seiyaku Kabushiki Kaisha Novel 3,4-diaminoquinoline and pyridine compounds
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
NZ551559A (en) 2004-05-24 2008-10-31 Equusys Inc Animal instrumentation
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN101466670B (zh) * 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
EP2066645A2 (en) * 2006-09-12 2009-06-10 UCB Pharma S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
WO2008122378A1 (en) * 2007-04-04 2008-10-16 Ucb Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EA201270051A1 (ru) 2009-06-25 2012-05-30 Амген Инк. Гетероциклические соединения и их применения
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2012003283A1 (en) * 2010-06-30 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
US9226929B2 (en) 2011-03-02 2016-01-05 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
CN106946796B (zh) * 2011-09-12 2020-05-08 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
ES2675760T3 (es) 2012-01-06 2018-07-12 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos y métodos de uso de los mismos
EP2912024B1 (en) * 2012-10-24 2016-07-20 Basf Se Herbicidal azines
CN103044469A (zh) * 2012-11-30 2013-04-17 大连联化化学有限公司 一种制备环戊烯/环己烯-1-硼酸频哪醇酯的方法
WO2014116594A1 (en) 2013-01-23 2014-07-31 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105517996B (zh) * 2013-07-11 2019-03-26 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
AU2014287121B2 (en) 2013-07-11 2018-11-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
KR102302091B1 (ko) * 2013-07-11 2021-09-16 아지오스 파마슈티컬스 아이엔씨. 암 치료용의 ｉｄｈ２ 돌연변이체 억제제로서의 ｎ,６-비스(아릴 또는 헤테로아릴)-１，３，５-트리아진-２,４-디아민 화합물
ES2886211T3 (es) 2013-08-02 2021-12-16 Agios Pharmaceuticals Inc Compuestos terapéuticamente activos y sus métodos de uso
SG11201601467SA (en) 2013-11-01 2016-05-30 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
SG11201609981RA (en) * 2014-06-04 2016-12-29 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
US10179790B2 (en) 2014-06-04 2019-01-15 Thomas Helledays Stiftelse For Medicinsk Forskning MTH1 inhibitors for treatment of cancer
HUE056537T2 (hu) * 2015-07-30 2022-02-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd 1,3,5-triazinszármazék és annak alkalmazási módszere
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
IL299563A (en) 2015-12-04 2023-02-01 Agios Pharmaceuticals Inc Methods of treatment of acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
WO2017096945A1 (zh) * 2015-12-07 2017-06-15 北京康美特科技股份有限公司 含硼有机硅化合物、太阳能电池组件用密封剂以及太阳能电池组件
LT3442947T (lt) 2016-04-15 2023-09-11 Epizyme, Inc. Aminu pakeisti arilo arba heteroarilo junginiai, kaip ehmt1 ir ehmt2 inhibitoriai
CN107382840B (zh) 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
SG11202001182QA (en) 2017-08-15 2020-03-30 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
SMT202200004T1 (it) 2017-09-07 2022-03-21 Eisai R&D Man Co Ltd Composto pentaciclico

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111132967A (zh) * 2017-09-07 2020-05-08 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
CN111132967B (zh) * 2017-09-07 2023-08-04 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
WO2022095756A1 (zh) * 2020-11-09 2022-05-12 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
CN116209655A (zh) * 2020-11-09 2023-06-02 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
WO2023134686A1 (zh) * 2022-01-11 2023-07-20 正大天晴药业集团股份有限公司 一种1,3,5-三嗪衍生物的制备方法

Also Published As

Publication number Publication date
US20210363115A2 (en) 2021-11-25
US20220372005A1 (en) 2022-11-24
IL272923B2 (en) 2023-06-01
CN111132967A (zh) 2020-05-08
EP3679020A1 (en) 2020-07-15
PE20200727A1 (es) 2020-07-23
JP2023103290A (ja) 2023-07-26
CN117797156A (zh) 2024-04-02
EP3679020A4 (en) 2021-05-05
CN111132967B (zh) 2023-08-04
JP7273030B2 (ja) 2023-05-12
CL2020000553A1 (es) 2020-08-07
US12234211B2 (en) 2025-02-25
JP2020533319A (ja) 2020-11-19
PH12020500408A1 (en) 2021-03-01
CN117257809A (zh) 2023-12-22
WO2019047909A1 (en) 2019-03-14
UA129118C2 (uk) 2025-01-22
CN117024363A (zh) 2023-11-10
JP7603740B2 (ja) 2024-12-20
TWI816693B (zh) 2023-10-01
TW201912632A (zh) 2019-04-01
NZ762447A (en) 2023-09-29
KR102566237B1 (ko) 2023-08-14
MX2020002505A (es) 2020-07-20
AU2018329047B2 (en) 2023-09-07
US20210163426A1 (en) 2021-06-03
BR112020004563A2 (pt) 2020-09-08
EA202090653A1 (ru) 2021-02-03
CN116999441A (zh) 2023-11-07
CA3073782A1 (en) 2019-03-14
US20250223267A1 (en) 2025-07-10
ZA202001448B (en) 2024-11-27
IL272923A (en) 2020-04-30
SG11202001642WA (en) 2020-03-30
JP7273030B6 (ja) 2024-02-15
US11414390B2 (en) 2022-08-16
AR112794A1 (es) 2019-12-11
AU2018329047A1 (en) 2020-03-12
KR20200052321A (ko) 2020-05-14

Similar Documents

Publication Publication Date Title
US12234211B2 (en) Cycloolefin substituted heteroaromatic compounds and their use
TW202142541A (zh) 用作激酶抑制劑的化合物及其應用
WO2024235286A1 (en) Tricyclic compounds and uses thereof
UA116534C2 (uk) Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
TW201805286A (zh) Ｆｇｆｒ４抑制劑及其製備方法和應用
CN111171020A (zh) 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN120225530A (zh) 异双官能化合物及治疗疾病的方法
KR20240167844A (ko) 질소 함유 헤테로시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용
JP2021501215A (ja) アミノ置換窒素含有縮合環化合物、その調製方法及び使用
WO2023046030A1 (zh) 一种egfr小分子抑制剂、含其的药物组合物及其用途
HK40027076A (en) Cycloolefin substituted heteroaromatic compounds and their use
HK40027076B (zh) 环烯烃取代的杂芳环类化合物及其用途
US20250320222A1 (en) Tricyclic compounds and uses thereof
NZ762447B2 (en) Cycloolefin substituted heteroaromatic compounds and their use
CN103319456B (zh) 二氢吡啶类化合物、其组合物、制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190315

WD01 Invention patent application deemed withdrawn after publication